Skip to contentB
BIO-TECHNE Corp
B
TECHBIO-TECHNE Corp Q3 2025 · 10-Q
Revenue$316.18M$316.18M+4.2% vs Q3 2024 Net Income$22.59M$22.59M−54.0% vs Q3 2024 EPS Diluted$0.14$0.14−54.8% vs Q3 2024 Gross Profit$214,556,000+4.9% Operating Income
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
BIO-TECHNE Corp · CIK 842023 · Engraved from SEC EDGAR
Operating Cash Flowderived$41,120,000−49.2% Free Cash Flowderived$30,997,000−52.0% Margins · derivedGross margin67.9%+0.4 pt vs Q3 2024
Operating margin12.2%−9.8 pt vs Q3 2024
Net margin7.1%−9.0 pt vs Q3 2024
ended Mar 31, 2025 · filed May 8, 2025 · 38 d after period end